Emergent BioSolutions (EBS) Share-based Compensation (2010 - 2026)

Emergent BioSolutions' Share-based Compensation history runs 17 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 280.0% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 88.89% decrease from a year earlier, with the FY2024 full-year figure at $18.0 million, down 22.08% from the prior year.
• Share-based Compensation grew to $1.9 million in Q1 2026 per EBS's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $20.7 million in Q4 2023 and bottomed at -$16.5 million in Q3 2022.
• The 5-year median for Share-based Compensation is $2.1 million (2023), against an average of $2.5 million.
• Biggest YoY gain for Share-based Compensation was 2050.0% in 2022; the steepest drop was 185.49% in 2022.
• Year by year, Share-based Compensation stood at -$5.7 million in 2022, then jumped by 463.16% to $20.7 million in 2023, then tumbled by 50.24% to $10.3 million in 2024, then slumped by 109.71% to -$1.0 million in 2025, then surged by 290.0% to $1.9 million in 2026.
• Per Business Quant, the three latest EBS Share-based Compensation figures stand at $1.9 million (Q1 2026), -$1.0 million (Q4 2025), and -$5.1 million (Q3 2025).